MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) Stock Price, Forecast & Analysis
Europe - BIT:1MDGL - US5588681057 - Common Stock
1MDGL.MI Key Statistics, Chart & Performance
The current stock price of 1MDGL.MI is 379.4 EUR.
1MDGL.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 67.74 | 44.96B | ||
| 1AE.DE | ARGENX SE | 67.72 | 44.95B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.95B | ||
| 2X1.DE | ABIVAX SA | N/A | 6.90B | ||
| ABVX.PA | ABIVAX SA | N/A | 6.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.77B | ||
| 5CV.DE | CUREVAC NV | 5.17 | 1.01B | ||
| NANO.PA | NANOBIOTIX | N/A | 820.61M | ||
| PHIL.MI | PHILOGEN SPA | 20.79 | 692.99M | ||
| IVA.PA | INVENTIVA SA | N/A | 517.80M | ||
| FYB.DE | FORMYCON AG | N/A | 341.03M | ||
| VLA.PA | VALNEVA SE | N/A | 314.28M |
Related stock screener links
About 1MDGL.MI
Company Profile
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Company Info
MADRIGAL PHARMACEUTICALS INC
200 Barr Harbor Dr Ste 400
West Conshohocken PENNSYLVANIA US
Employees: 528
Phone: 14043809263
MADRIGAL PHARMACEUTICALS INC / 1MDGL.MI FAQ
What does MADRIGAL PHARMACEUTICALS INC do?
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
What is the stock price of MADRIGAL PHARMACEUTICALS INC today?
The current stock price of 1MDGL.MI is 379.4 EUR.
Does 1MDGL stock pay dividends?
1MDGL.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1MDGL stock?
1MDGL.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) stock traded?
1MDGL.MI stock is listed on the Euronext Milan exchange.
Can you provide the upcoming earnings date for MADRIGAL PHARMACEUTICALS INC?
MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) will report earnings on 2026-02-24, after the market close.
1MDGL.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1MDGL.MI.
1MDGL.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1MDGL.MI. While 1MDGL.MI seems to be doing ok healthwise, there are quite some concerns on its profitability.
1MDGL.MI Financial Highlights
Over the last trailing twelve months 1MDGL.MI reported a non-GAAP Earnings per Share(EPS) of -11.14. The EPS increased by 49.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.76% | ||
| ROE | -40.5% | ||
| Debt/Equity | 0.17 |
1MDGL.MI Forecast & Estimates
23 analysts have analysed 1MDGL.MI and the average price target is 443.79 EUR. This implies a price increase of 16.97% is expected in the next year compared to the current price of 379.4.
For the next year, analysts expect an EPS growth of 54.89% and a revenue growth 402% for 1MDGL.MI